Sat, Apr 19, 2014, 7:39 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Valeant Pharmaceuticals International, Inc. Message Board

  • voyvik11 voyvik11 Nov 9, 2012 1:18 PM Flag

    Deal is crashing. - Sold my shares - its a falling knife

    Medicis (MRX) is falling after the company disclosed in an SEC filing that it had been sued by dermatological product maker Q-Med. The lawsuit alleges that Q-Med has the right to block Medicis' pending merger with Valenant Pharmaceuticals (VRX). Q-Med, whose dermal filler products are sold by Medicis, is asking a court to affirm that it has the right to block the merger, as well as a preliminary injunction that would prohibit Medicis from transferring to Valeant its right to distribute Q-Med products.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • BIG ouch if you bailed at $42!
      I hope you recapture some with option trading.
      I am betting that Allergan(AGN), has the edge with superior product offering in the lucrative aesthetic space; plus way better, and proven mgmt and -- more importantly -- an advantageous cash position.
      I am going long AGN; and will use VRX as a periodic trading play, until it's character, and it's position is defined, after the MRX legal imbroglio is settled, and the deal is consummated.
      Until then, VRX remains muddled with all kinds of risk, brought about by a legally uncertain environment.
      It is not a prudent place for any self-respecting, individual investor's hard-earned-cash...
      no matter what the "pro's at Barrons" are prognosticating...

    • Although it does look like this deal continues to proceed, I too am concerned. Valeant's merger with Medicis would be stepping on some pretty big toes. Q-Med, which is owned by Swiss Pharm, Galderma, is itself a joint venture between Nestle and L'Oréal - two very big Global Fish. And they don't like the idea that their new largest competitor (Valeant) will be earning profits off Restylane and Perlane injections (Restylane could surpass Botox as the new preferred dermal filler). But instead of a wholesale merger retreat, Valeant might just have to make a separate Restylane distribution deal. I’d like to see them get compensated, but Nestle and L'Oréal have such enormous resources that Valeant might not wish to fight that battle. We’ll just have to wait and see.

 
VRX
122.05+0.60(+0.49%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.